U.S. markets open in 1 hour 37 minutes
  • S&P Futures

    4,127.25
    +3.75 (+0.09%)
     
  • Dow Futures

    33,888.00
    -46.00 (-0.14%)
     
  • Nasdaq Futures

    12,558.25
    +42.75 (+0.34%)
     
  • Russell 2000 Futures

    1,964.40
    -0.70 (-0.04%)
     
  • Crude Oil

    75.35
    +1.24 (+1.67%)
     
  • Gold

    1,884.50
    +5.00 (+0.27%)
     
  • Silver

    22.30
    +0.06 (+0.28%)
     
  • EUR/USD

    1.0709
    -0.0022 (-0.20%)
     
  • 10-Yr Bond

    3.6340
    0.0000 (0.00%)
     
  • Vix

    19.46
    +1.13 (+6.16%)
     
  • GBP/USD

    1.1981
    -0.0043 (-0.36%)
     
  • USD/JPY

    132.1350
    -0.4720 (-0.36%)
     
  • BTC-USD

    23,026.29
    +99.46 (+0.43%)
     
  • CMC Crypto 200

    529.20
    +4.07 (+0.77%)
     
  • FTSE 100

    7,879.96
    +43.25 (+0.55%)
     
  • Nikkei 225

    27,685.47
    -8.18 (-0.03%)
     

Growth Investors: Industry Analysts Just Upgraded Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenue Forecasts By 27%

Caribou Biosciences, Inc. (NASDAQ:CRBU) shareholders will have a reason to smile today, with the analysts making substantial upgrades to next year's statutory forecasts. The revenue forecast for next year has experienced a facelift, with the analysts now much more optimistic on its sales pipeline.

After the upgrade, the seven analysts covering Caribou Biosciences are now predicting revenues of US$21m in 2023. If met, this would reflect a huge 59% improvement in sales compared to the last 12 months. Per-share losses are expected to explode, reaching US$2.06 per share. Yet before this consensus update, the analysts had been forecasting revenues of US$17m and losses of US$2.11 per share in 2023. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to next year's revenue estimates, while at the same time reducing their loss estimates.

Check out our latest analysis for Caribou Biosciences

earnings-and-revenue-growth
earnings-and-revenue-growth

Of course, another way to look at these forecasts is to place them into context against the industry itself. It's pretty clear that there is an expectation that Caribou Biosciences' revenue growth will slow down substantially, with revenues to the end of 2023 expected to display 45% growth on an annualised basis. This is compared to a historical growth rate of 155% over the past year. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 14% annually. Even after the forecast slowdown in growth, it seems obvious that Caribou Biosciences is also expected to grow faster than the wider industry.

The Bottom Line

The most important thing here is that analysts reduced their loss per share estimates for next year, reflecting increased optimism around Caribou Biosciences' prospects. They also upgraded their revenue estimates for next year, and sales are expected to grow faster than the wider market. Seeing the dramatic upgrade to next year's forecasts, it might be time to take another look at Caribou Biosciences.

Analysts are clearly in love with Caribou Biosciences at the moment, but before diving in - you should be aware that we've identified some warning flags with the business, such as recent substantial insider selling. You can learn more, and discover the 3 other concerns we've identified, for free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here